Latest news with #8.8
India.com
02-07-2025
- Entertainment
- India.com
This web series has won 43 awards, based on true events, has an 8.8 IMDb rating, lead actors are..., series is...
This series is among the highest-rated Hindi shows on IMDb, boasting a rating of 8.8. It has garnered a total of 43 awards, and the performances of the cast were highly praised. If you haven't watched it yet, make sure to do so right away. One Of The Most Finest Series On OTT The series we are talking about is Rocket Boys, which tells the true story of scientists Homi J. Bhabha and Vikram Sarabhai. The narrative unfolds during the pivotal decades of the 1940s to the 1960s in India, showcasing the country's journey towards becoming a strong, courageous, and independent nation. It highlights the early years of Independent India in the realm of science. With aspirations in their hearts and a vision in their minds, Dr. Homi J. Bhabha spearheaded India's Nuclear Programme, while Dr. Vikram Sarabhai laid the foundation for the Indian Space Programme and various other institutions. The Positive Reception And Accolades For Rocket Boys This series consists of 16 episodes spread across two seasons. Key roles were played by Jim Sarbh, Ishwak Singh, Regina Cassandra, Saba Azad, Divyendu Bhattacharya, and Rajit Kapoor. According to IMDb, the series has won 43 awards, encompassing both minor and major accolades. It received the Best Web Series award from the Indian Television Academy. Abhay Pannu and Kausar Munir were honored with the ITA Award for Best Dialogue. Jim Sarbh won the ITA Award for Best Actor, and the series also received awards for Best Story, Best Editing, Best VFX, and Best Director. More About Rocket Boys Additionally, Jim Sarbh was awarded the Dadasaheb Phalke International Award for Best Actor. The series won the Filmfare Award for Best Screenplay, and Abhay Pannu was recognized with the Filmfare Award for Best Director. It also received the Filmfare Award for Best Web Series (Popular Award). The theme, soundtrack, and score for both seasons were composed by Achint Thakkar, who gained recognition from Hansal Mehta's Scam 1992. Both series are currently streaming on Sony-LIV
Time of India
18-06-2025
- Automotive
- Time of India
RTI: Eway e-challan recovery just 9 per cent of 269cr
The Intelligent Traffic Management System (ITMS) on Mumbai-Pune expressway has generated 17 lakh e-challans worth nearly ₹ 269.5 crore for traffic violations since it was implemented on July 19 last year, but recovery from offenders stands at a measly 9per cent till March 2025, officials said on Sunday. The 1.5 lakh cleared e-challans, or 9per cent of the total generated, amount to ₹25.2 crore, which is 9.3 per cent of the total sum to be paid by offenders, as per official documents. As per an RTI reply, Maharashtra government has paid the ITMS operator ₹57.9 crore for the 8.8 lakh e-challans issued between July 19 and Dec 31 last year. The project is being executed by the Maharashtra State Road Development Corporation (MSRDC), which built the Mumbai-Pune expressway, in collaboration with the RTO and highway police under a Public-Private Partnership ( PPP ) model. The state transport department has given ₹45 crore viability gap funding from Road Safety Fund for the project that costs more than ₹100 crore. The MSRTC has installed 40 gantries and hundreds of CCTV cameras as part of ITMS, which also includes speed detection cameras , ANPR, weigh-in-motion sensors, AVCC, weather sensors, and a dynamic messaging system.
Time of India
16-06-2025
- Automotive
- Time of India
Mumbai-Pune expressway ITMS flags ₹269 crore in fines, recovers just 9%, ET Infra
Advt Join the community of 2M+ industry professionals. Subscribe to Newsletter to get latest insights & analysis in your inbox. Get updates on your preferred social platform Follow us for the latest news, insider access to events and more. The Intelligent Traffic Management System (ITMS) on Mumbai-Pune expressway has generated 17 lakh e-challans worth nearly ₹269.5 crore for traffic violations since it was implemented on July 19 last year, but recovery from offenders stands at a measly 9 per cent till March 2025, officials said on 1.5 lakh cleared e-challans, or 9 per cent of the total generated, amount to ₹25.2 crore, which is 9.3 per cent of the total sum to be paid by offenders, as per official per an RTI reply, Maharashtra government has paid the ITMS operator ₹57.9 crore for the 8.8 lakh e-challans issued between July 19 and December 31 last project is being executed by the Maharashtra State Road Development Corporation (MSRDC), which built the Mumbai-Pune expressway, in collaboration with the RTO and highway police under a Public-Private Partnership (PPP) state transport department has given ₹45 crore viability gap funding from Road Safety Fund for the project that costs more than ₹100 MSRTC has installed 40 gantries and hundreds of CCTV cameras as part of ITMS, which also includes speed detection cameras, ANPR, weigh-in-motion sensors, AVCC, weather sensors, and a dynamic messaging system.
Mint
02-06-2025
- Business
- Mint
India's GDP: A key test lies ahead
The fiscal policy-led rescue of India's economy from the covid shock has been impressive, even though its pace of expansion slowed to 6.5% in 2024-25, as provisional data shows, after a three-year run averaging above 8.8%. Last year's rate of GDP growth dropped below the path demanded by Viksit Bharat, but the second half's acceleration reveals a grip on its gear-stick held by the government through public expenditure. How long, though, will state support last? Also Read: Kaushik Basu: Redefine prosperity; GDP tunnel-vision could prove costly Last year's fiscal gap was under 4.8% and this year's 4.4% goal is achievable. After that, public debt will be adopted as the official gauge to constrain risky over-spending. Also Read: It's time to lay the great Indian GDP controversy to rest Clearly, India's Fiscal Responsibility and Budget Management (FRBM) law needs rework in the light of lessons from our economic recovery. How 2025-26 turns out may be instructive. If inflation stays subdued at around 4%, the central bank's aim, even with the fiscal deficit exceeding the FRBM's 3% cap, it'll be a relief. Also Read: The state of India's economy is not as bright as GDP data may suggest What happens to price stability if private investment and consumption regain full strength, however, remains untested. It's a key test, as faster growth and lower debt require both these to form a robust mutually reinforcing loop.
Business Insider
23-05-2025
- Health
- Business Insider
Cullinan Therapeutics to present new results from REZILIENT1 trial
Cullinan Therapeutics (CGEM), Taiho Pharmaceutical and Taiho Oncology announced new results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations who have received prior therapy. These data will be presented on Sunday, June 1 at the American Society of Clinical Oncology annual meeting as an oral presentation. As of the December 2024 data cutoff, 244 patients were enrolled in REZILIENT1 and received at least one dose of 100 mg zipalertinib. The overall efficacy population consisted of all patients who received at least one dose of 100 mg zipalertinib and had approximately 8 months of minimum follow-up at data cutoff. Patients had received a median of 2 prior therapies, and 39% of patients had a history of brain metastases. With median follow-up of 9.3 months, zipalertinib demonstrated: In the overall efficacy population, confirmed overall objective response rate was 35% with median duration of response of 8.8 months; in patients with prior platinum-based chemotherapy only, ORR was 40% with mDOR of 8.8 months, consistent with REZILIENT1 Phase 1/2a results; in patients with prior chemo and amivantamab, ORR was 30% with mDOR of 14.7 months; in patients with prior chemo and amivantamab, ORR was 24% with mDOR of 8.5 months and in patients with brain metastases, the ORR was 31% with mDOR of 8.3 months. The safety analysis population included all REZILIENT1 patients who received at least one dose of 100 mg zipalertinib. The results showed that zipalertinib demonstrated a manageable safety profile in this heavily pre-treated patient population, consistent with previously reported data. The most common treatment-related adverse events were paronychia, rash, dermatitis acneiform, dry skin, diarrhea and stomatitis. The majority of TRAEs were grade 1 or 2. The most common grade 3 TRAEs were anemia, pneumonitis and rash, increased alanine aminotransferase, diarrhea, and decreased platelet count.
